Neuberger Berman Group
PBYI icon

Neuberger Berman Group’s Puma Biotechnology PBYI Stock Holding History

Neuberger Berman Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,000
Closed -$296K – 1680
2018
Q2 		$296K Buy
+5,000
New +$290K ﹤0.01% 1523
2018
Q1 		– Sell
-2,400
Closed -$237K – 1726
2017
Q4 		$237K Sell
2,400
-4,100
-63% -$459K ﹤0.01% 1638
2017
Q3 		$778K Sell
6,500
-10,700
-62% -$995K ﹤0.01% 1208
2017
Q2 		$1.5M Buy
+17,200
New +$962K ﹤0.01% 1064
2015
Q2 		– Sell
-63,000
Closed -$14.9M – 1598
2015
Q1 		$14.9M Sell
63,000
-64
-0.1% -$13.7K 0.02% 762
2014
Q4 		$11.9M Sell
63,064
-3,600
-5% -$799K 0.01% 791
2014
Q3 		$15.9M Buy
+66,664
New +$13.7M 0.02% 736

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Neuberger Berman Group's PBYI Position: Q3 2018 in Review

Neuberger Berman Group sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 5,000 shares — an estimated $296K sold.

Neuberger Berman Group first reported a position in PBYI in Q3 2014 and held it in 7 quarters. The position peaked at $15.9M in Q3 2014. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

  • Neuberger Berman Group reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 5,000 Puma Biotechnology shares in Q3 2018, an estimated $296K.
  • Neuberger Berman Group first reported a position in Puma Biotechnology in Q3 2014 and held it in 7 quarters.
  • Neuberger Berman Group's Puma Biotechnology position peaked at $15.9M in Q3 2014.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Neuberger Berman Group's 13F filing for Q3 2018, filed 13 Nov 2018.